Condition
MET Exon 14 Skipping Mutation
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Enrolling By Invitation1
Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07122882Enrolling By Invitation
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
NCT05800340Phase 2Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
NCT04647838Phase 2Unknown
Tepotinib in Solid Tumors Harboring MET Alterations
Showing all 3 trials